Article Information
History
- October 9, 2023.
Article Versions
- You are currently viewing Version 1 of this article (October 9, 2023 - 11:13).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jörn Lötsch1,2,a,
- Khayal Gasimli3,a,
- Sebastian Malkusch1,2,
- Lisa Hahnefeld1,2,
- Carlo Angioni1,
- Yannick Schreiber2,
- Sandra Trautmann1,2,
- Saskia Wedel1,
- Dominique Thomas1,2,
- Nerea Ferreiros Bouzas1,2,
- Christian Brandts4,5,
- Benjamin Schnappauf6,
- Christine Solbach3,
- Gerd Geisslinger1,2 and
- Marco Sisignano1,2,*
- 1Institute of Clinical Pharmacology, Goethe - University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
- 2Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Theodor-Stern-Kai 7, 60596 Frankfurt am Main, Germany
- 3Goethe University, Department of Gynecology and Obstetrics, Theodor-Stern-Kai 7, Frankfurt/Main, Germany
- 4German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany
- 5Goethe University, University Cancer Center Frankfurt (UCT), Goethe University Hospital, Frankfurt am Main 60590, Germany
- 6Oncology Center, Sana-Klinikum Offenbach, Starkenburgring 66, 63069 Offenbach
- ↵*Correspondence to: Marco Sisignano, PhD, Goethe-University, Theodor - Stern - Kai 7, 60590 Frankfurt am Main, Germany, e-mail: Marco.Sisignano{at}med.uni-frankfurt.de, Phone:, +49-69-6301-87819, Fax: +49-69-6301-83378
↵a these authors contributed equally
Posted October 09, 2023.
Machine learning and biological validation identify sphingolipids as key mediators of paclitaxel-induced neuropathy in cancer patients
